Literature DB >> 16790461

Probiotics for prevention of recurrent vulvovaginal candidiasis: a review.

Matthew E Falagas1, Gregoria I Betsi, Stavros Athanasiou.   

Abstract

Vulvovaginal candidiasis (VVC) is a common infection affecting the quality of life of many women. Probiotics have been investigated as possible agents for the prevention of recurrences of VVC. We reviewed the available literature. In some studies the development of VVC was associated with either a low number of lactobacilli in the vagina or with the presence of H2O2-non-producing vaginal lactobacilli, although there are a few studies not supporting these statements. In addition, in vitro studies have shown that lactobacilli can inhibit the growth of Candida albicans and/or its adherence on the vaginal epithelium. The results of some clinical trials support the effectiveness of lactobacilli, especially Lactobacillus acidophilus, Lactobacillus rhamnosus GR-1 and Lactobacillus fermentum RC-14, administered either orally or intravaginally in colonizing the vagina and/or preventing the colonization and infection of the vagina by C. albicans, while the results of a small number of clinical trials do not corroborate these findings. Nevertheless, most of the relevant clinical trials had methodological problems such as small sample size, no control group (placebo) and included women without confirmed recurrent VVC, and thus they are not reliable for drawing definitive conclusions. Thus, the available evidence for the use of probiotics for prevention of recurrent VVC is limited. However, the empirical use of probiotics may be considered in women with frequent recurrence of VVC (more than three episodes per year), especially for those who have adverse effects from or contraindications for the use of antifungal agents, since adverse effects of probiotics are very rare. In any case women should be clearly informed about the unproven usefulness of probiotics for this purpose. In conclusion, despite the promising results of some studies, further research is needed to prove the effectiveness of probiotics in preventing the recurrences of VVC and to allow their wide use for this indication.

Entities:  

Mesh:

Year:  2006        PMID: 16790461     DOI: 10.1093/jac/dkl246

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  53 in total

Review 1.  Candida albicans Biofilms and Human Disease.

Authors:  Clarissa J Nobile; Alexander D Johnson
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

Review 2.  Anticandidal immunity and vaginitis: novel opportunities for immune intervention.

Authors:  Antonio Cassone; Flavia De Bernardis; Giorgio Santoni
Journal:  Infect Immun       Date:  2007-06-11       Impact factor: 3.441

3.  Practical identification of human originated Lactobacillus species by amplified ribosomal DNA restriction analysis (ARDRA) for probiotic use.

Authors:  Mehmet Öztürk; Merve Meterelliyöz
Journal:  Mol Biol Rep       Date:  2015-04-10       Impact factor: 2.316

Review 4.  Recurrent vulvovaginal candidiasis.

Authors:  Mathieos Belayneh; Evan Sehn; Christina Korownyk
Journal:  Can Fam Physician       Date:  2017-06       Impact factor: 3.275

Review 5.  A review of the pharmacobiotic regulation of gastrointestinal inflammation by probiotics, commensal bacteria and prebiotics.

Authors:  L Vitetta; D Briskey; E Hayes; C Shing; J Peake
Journal:  Inflammopharmacology       Date:  2012-03-18       Impact factor: 4.473

6.  Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013).

Authors:  W Mendling; K Friese; I Mylonas; E-R Weissenbacher; J Brasch; M Schaller; P Mayser; I Effendy; G Ginter-Hanselmayer; H Hof; O Cornely; M Ruhnke
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-04       Impact factor: 2.915

7.  Interactions of Lactobacilli with pathogenic Streptococcus pyogenes.

Authors:  Mark L Westbroek; Crystal L Davis; Lena S Fawson; Travis M Price
Journal:  Infect Dis Obstet Gynecol       Date:  2010-05-24

Review 8.  Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings.

Authors:  Lay-Gaik Ooi; Min-Tze Liong
Journal:  Int J Mol Sci       Date:  2010-06-17       Impact factor: 5.923

9.  Functional and probiotic attributes of an indigenous isolate of Lactobacillus plantarum.

Authors:  Jai K Kaushik; Ashutosh Kumar; Raj K Duary; Ashok K Mohanty; Sunita Grover; Virender K Batish
Journal:  PLoS One       Date:  2009-12-01       Impact factor: 3.240

10.  Prevention and treatment of urinary tract infection with probiotics: Review and research perspective.

Authors:  D Borchert; L Sheridan; A Papatsoris; Z Faruquz; J M Barua; I Junaid; Y Pati; F Chinegwundoh; N Buchholz
Journal:  Indian J Urol       Date:  2008-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.